Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 14, 2008

Cordis to Supply Catheters for Gamida-Cell’s Cardiovascular Candidate

  • Cordis’ biologics delivery systems group will supply catheters for the upcoming Phase I/II clinical trial of Gamida Cell’s CardioCure product for the treatment of post-myocardial infarction  patients. CardioCure is a ex-vivo expanded autologous  bone marrow product.

    The randomized, controlled multicenter Phase I/II trial, due to start in Q4 2008 in Israel, will evaluate the safety and efficacy of Gamida-Cell’s CardioCure in 48 post-MI patients. CardioCure will be injected directly into the myocardium using the latest generation of the NOGA® Cardiac Navigation System and MyoStar® Injection Catheter.

    “The NOGA® XP Cardiac Navigation System is a highly sophisticated and accurate electro-guided methodology, which creates precise, 3-dimensional images of the heart. This will enable us to identify damaged myocardial tissue and accurately deliver the CardioCure injections into the relevant area in order to assist with functional restoration of the damaged heart,” says Ran Kornowski, Ph.D., director of interventional cardiology and cardiac catheterization laboratories at the Rabin Medical Center and a leading principal investigator in the Gamida-Cell CardioCure clinical study.